Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Neoplasms | 11 | 2023 | 144 | 1.470 |
Why?
|
| Retinoblastoma | 10 | 2023 | 200 | 1.260 |
Why?
|
| Ependymoglial Cells | 1 | 2022 | 4 | 0.860 |
Why?
|
| Prealbumin | 1 | 2022 | 37 | 0.850 |
Why?
|
| Giant Cell Arteritis | 5 | 2021 | 57 | 0.740 |
Why?
|
| Uveal Neoplasms | 5 | 2022 | 176 | 0.720 |
Why?
|
| Temporal Arteries | 5 | 2021 | 40 | 0.400 |
Why?
|
| Vitreous Body | 7 | 2023 | 123 | 0.380 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 100 | 0.360 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 224 | 0.340 |
Why?
|
| Retina | 5 | 2022 | 532 | 0.310 |
Why?
|
| Biopsy | 10 | 2021 | 3443 | 0.300 |
Why?
|
| Sclera | 2 | 2018 | 69 | 0.300 |
Why?
|
| Intraocular Lymphoma | 2 | 2016 | 15 | 0.280 |
Why?
|
| Orbital Diseases | 2 | 2018 | 118 | 0.280 |
Why?
|
| Eye Neoplasms | 2 | 2023 | 247 | 0.250 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 690 | 0.240 |
Why?
|
| Retinitis | 1 | 2023 | 19 | 0.230 |
Why?
|
| Eye Infections, Viral | 1 | 2023 | 30 | 0.230 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2023 | 171 | 0.230 |
Why?
|
| Ciliary Body | 2 | 2022 | 35 | 0.220 |
Why?
|
| Eye Enucleation | 6 | 2022 | 91 | 0.210 |
Why?
|
| Fluoresceins | 1 | 2022 | 73 | 0.210 |
Why?
|
| Optic Nerve Injuries | 1 | 2022 | 12 | 0.210 |
Why?
|
| Calciphylaxis | 1 | 2021 | 4 | 0.210 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2018 | 137 | 0.210 |
Why?
|
| Vasculitis | 1 | 2021 | 61 | 0.200 |
Why?
|
| Cataract | 1 | 2022 | 218 | 0.190 |
Why?
|
| Eye Diseases | 2 | 2016 | 132 | 0.180 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 71 | 0.180 |
Why?
|
| Graves Ophthalmopathy | 1 | 2019 | 22 | 0.180 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 108 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 179 | 0.170 |
Why?
|
| Mucins | 1 | 2020 | 285 | 0.170 |
Why?
|
| Retinal Vasculitis | 1 | 2018 | 10 | 0.170 |
Why?
|
| Visual Acuity | 3 | 2018 | 873 | 0.170 |
Why?
|
| Orbit | 2 | 2017 | 205 | 0.170 |
Why?
|
| Siphonaptera | 1 | 2018 | 8 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 502 | 0.160 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 37 | 0.160 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2018 | 13 | 0.160 |
Why?
|
| Oculomotor Muscles | 1 | 2019 | 179 | 0.160 |
Why?
|
| Strabismus | 1 | 2019 | 213 | 0.160 |
Why?
|
| Hemianopsia | 1 | 2018 | 42 | 0.160 |
Why?
|
| Retinal Vessels | 1 | 2018 | 85 | 0.160 |
Why?
|
| Sphenoid Sinus | 1 | 2017 | 21 | 0.160 |
Why?
|
| Electroretinography | 4 | 2018 | 116 | 0.160 |
Why?
|
| Family | 1 | 2022 | 736 | 0.160 |
Why?
|
| Insect Bites and Stings | 1 | 2018 | 43 | 0.160 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 1021 | 0.160 |
Why?
|
| Porphyrins | 1 | 2017 | 37 | 0.160 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2021 | 273 | 0.160 |
Why?
|
| Polychondritis, Relapsing | 1 | 2017 | 6 | 0.150 |
Why?
|
| Triamcinolone Acetonide | 2 | 2008 | 38 | 0.150 |
Why?
|
| Visual Fields | 1 | 2018 | 142 | 0.150 |
Why?
|
| Ribonuclease III | 1 | 2018 | 182 | 0.150 |
Why?
|
| Orbital Pseudotumor | 1 | 2017 | 13 | 0.150 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2017 | 45 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2017 | 96 | 0.150 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 1516 | 0.150 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2018 | 255 | 0.140 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 13658 | 0.140 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2018 | 144 | 0.140 |
Why?
|
| Neoplasm Seeding | 1 | 2016 | 66 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 203 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 2 | 2021 | 895 | 0.140 |
Why?
|
| Melanoma | 3 | 2018 | 5317 | 0.130 |
Why?
|
| Eye Infections, Fungal | 1 | 2016 | 71 | 0.130 |
Why?
|
| Rabbits | 6 | 2017 | 957 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2023 | 14889 | 0.130 |
Why?
|
| Papilledema | 1 | 2016 | 85 | 0.130 |
Why?
|
| Optic Nerve | 1 | 2016 | 133 | 0.130 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 426 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1014 | 0.120 |
Why?
|
| Aspergillosis | 1 | 2016 | 246 | 0.120 |
Why?
|
| Humans | 36 | 2023 | 261506 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 750 | 0.120 |
Why?
|
| Filtering Surgery | 1 | 2013 | 6 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2016 | 256 | 0.120 |
Why?
|
| Exotropia | 1 | 2013 | 23 | 0.120 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2013 | 38 | 0.120 |
Why?
|
| Diplopia | 1 | 2013 | 66 | 0.120 |
Why?
|
| Brachytherapy | 2 | 2018 | 977 | 0.120 |
Why?
|
| Silver | 1 | 2013 | 34 | 0.120 |
Why?
|
| Ophthalmoplegia | 1 | 2013 | 79 | 0.110 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2017 | 489 | 0.110 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2013 | 73 | 0.110 |
Why?
|
| Glaucoma | 1 | 2013 | 92 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 121 | 0.110 |
Why?
|
| Aqueous Humor | 2 | 2022 | 29 | 0.100 |
Why?
|
| Ophthalmic Artery | 2 | 2023 | 25 | 0.100 |
Why?
|
| Radiotherapy | 2 | 2016 | 1824 | 0.100 |
Why?
|
| Male | 22 | 2022 | 123000 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 164 | 0.100 |
Why?
|
| Myocarditis | 1 | 2013 | 190 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.100 |
Why?
|
| Infant | 7 | 2023 | 13310 | 0.100 |
Why?
|
| Corneal Opacity | 1 | 2010 | 23 | 0.090 |
Why?
|
| Paraproteinemias | 1 | 2010 | 61 | 0.090 |
Why?
|
| Corneal Stroma | 1 | 2010 | 80 | 0.090 |
Why?
|
| Middle Aged | 16 | 2020 | 86204 | 0.080 |
Why?
|
| Child, Preschool | 7 | 2022 | 16273 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2578 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2023 | 12873 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2016 | 1411 | 0.080 |
Why?
|
| Female | 19 | 2023 | 141928 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2013 | 629 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2008 | 461 | 0.080 |
Why?
|
| Aged | 13 | 2020 | 70117 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 4744 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2018 | 7702 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 1226 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2008 | 298 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2023 | 37905 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2023 | 2292 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2022 | 3981 | 0.060 |
Why?
|
| Adult | 10 | 2023 | 77950 | 0.060 |
Why?
|
| Erdheim-Chester Disease | 1 | 2004 | 53 | 0.060 |
Why?
|
| Sirolimus | 1 | 2009 | 814 | 0.060 |
Why?
|
| Conjunctival Neoplasms | 1 | 2005 | 120 | 0.060 |
Why?
|
| Tomography, Optical Coherence | 2 | 2018 | 501 | 0.060 |
Why?
|
| Ophthalmoscopy | 2 | 2017 | 35 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 585 | 0.060 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 224 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 2390 | 0.060 |
Why?
|
| Optic Nerve Diseases | 1 | 2004 | 103 | 0.060 |
Why?
|
| Injections | 3 | 2008 | 285 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8873 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 1375 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 29902 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 8865 | 0.050 |
Why?
|
| Dyspnea | 1 | 2004 | 416 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 436 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 834 | 0.050 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 550 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3890 | 0.040 |
Why?
|
| North America | 1 | 2020 | 314 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2021 | 245 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 3168 | 0.040 |
Why?
|
| Slit Lamp Microscopy | 1 | 2018 | 6 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 1439 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 7789 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 73 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 232 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 338 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 4367 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 15862 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6100 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2023 | 32848 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 71 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 2173 | 0.040 |
Why?
|
| Lymphoma | 1 | 2005 | 1467 | 0.040 |
Why?
|
| Disease Management | 2 | 2016 | 1052 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 573 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 6682 | 0.040 |
Why?
|
| Child | 4 | 2023 | 29154 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2018 | 371 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 666 | 0.030 |
Why?
|
| Developing Countries | 2 | 2008 | 315 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2016 | 63 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 183 | 0.030 |
Why?
|
| Animals | 7 | 2018 | 59536 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1351 | 0.030 |
Why?
|
| Risk Factors | 3 | 2022 | 17523 | 0.030 |
Why?
|
| Prognosis | 3 | 2020 | 21713 | 0.030 |
Why?
|
| Young Adult | 3 | 2018 | 21445 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 250 | 0.030 |
Why?
|
| Heart Block | 1 | 2013 | 48 | 0.030 |
Why?
|
| Blister | 1 | 2013 | 31 | 0.030 |
Why?
|
| Bradycardia | 1 | 2013 | 70 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2013 | 257 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1910 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 631 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2013 | 127 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2013 | 146 | 0.030 |
Why?
|
| Methotrexate | 1 | 2016 | 999 | 0.030 |
Why?
|
| Mitomycin | 1 | 2013 | 208 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2013 | 355 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8223 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 7548 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 984 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3033 | 0.020 |
Why?
|
| Biomarkers | 2 | 2016 | 5047 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 5539 | 0.020 |
Why?
|
| Piperidines | 1 | 2016 | 1035 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 2315 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2010 | 73 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 726 | 0.020 |
Why?
|
| Etoposide | 1 | 2012 | 870 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 1299 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 5687 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3821 | 0.020 |
Why?
|
| Carboplatin | 1 | 2012 | 823 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 7551 | 0.020 |
Why?
|
| Adalimumab | 1 | 2008 | 38 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 1391 | 0.020 |
Why?
|
| Uveitis | 1 | 2008 | 33 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 3842 | 0.020 |
Why?
|
| Minerals | 1 | 2008 | 71 | 0.020 |
Why?
|
| Choroid | 1 | 2008 | 35 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 204 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 259 | 0.020 |
Why?
|
| Acetates | 1 | 2008 | 105 | 0.020 |
Why?
|
| Vincristine | 1 | 2012 | 1511 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2008 | 156 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2016 | 1423 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2016 | 1471 | 0.020 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2007 | 14 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 6295 | 0.020 |
Why?
|
| Internationality | 1 | 2008 | 208 | 0.020 |
Why?
|
| Macular Edema | 1 | 2008 | 99 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 548 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3230 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 621 | 0.020 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 1 | 2005 | 30 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 664 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5159 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1656 | 0.020 |
Why?
|
| Vimentin | 1 | 2007 | 253 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 620 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 1863 | 0.020 |
Why?
|
| Neuroglia | 1 | 2007 | 223 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1225 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 1165 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2016 | 3518 | 0.010 |
Why?
|
| Internet | 1 | 2008 | 706 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 1538 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 2231 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 3260 | 0.010 |
Why?
|
| Macrophages | 1 | 2007 | 1304 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 7222 | 0.010 |
Why?
|
| United States | 1 | 2016 | 15433 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 31252 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 10035 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 2403 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 3251 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 6869 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12221 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 14289 | 0.010 |
Why?
|
CHEVEZ-BARRIOS's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(242)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_